title: Diabetes-associated depression: the serotonergic system as a novel multifunctional target.
abstract: Diabetes associated depression is a largely understudied field which nonetheless carries a significant disease burden. The very low therapeutic efficacy of the existing conventional drugs with poor outcome may be, in part, due to uncertainty of the mechanism involved that clearly explains the existing comorbidity. The main purpose of this review was to address the sophisticated mechanisms of this comorbidity with a view of developing potential novel targets with higher efficacy and specificity. Data were collected from database searches including PubMed, references from relevant English language research/review articles and other official publications. Articles from 1990 to 2013 were included, and a broad search term criteria were followed for data mining so that relevant information was not missed out. Some of the search terms used included; diabetes-induced depression, diabetes and serotonin, hypothalamic-pituitary-adrenal (HPA) axis and diabetes and glucocorticoids in diabetes. Neuropathologically, depletion of brain monoaminergic activity specifically the serotonin (5-hydroxytryptamine [5-HT]) system, due to chronically persisting diabetic state may lead to the mood and behavioral complications that further add on worsening the quality life years. The 5-HT system through multifunctional tasks regulates neurogenesis and plasticity and by complex receptor mechanism controls the emotional and behavioral activity. Persisting hyperglycemia leads to impaired neurogenesis, decreased synaptic plasticity, undesired neuro-anatomical alterations, neurochemical deficits, and reduced neurotransmitter activity. The neurotrophic factors and secondary messenger functions affected at molecular and genetic levels indicate the impact of diabetes-mediated dysregulation on neuronal circuits. HPA activity, glycogen synthase kinase 3, and insulin signaling controls were also found to be hampered, interlinked to 5-HT system following diabetic progression.
authors.affiliation: Department of Pharmacy and, Birla Institute of Technology and Science, Pilani, Rajasthan, India.
authors.forename: Visakh
authors.initials: V
authors.lastname: Prabhakar
authors.affiliation: Department of Pharmacy and, Birla Institute of Technology and Science, Pilani, Rajasthan, India.
authors.forename: Deepali
authors.initials: D
authors.lastname: Gupta
authors.affiliation: Department of Pharmacy and, Birla Institute of Technology and Science, Pilani, Rajasthan, India.
authors.forename: Prateek
authors.initials: P
authors.lastname: Kanade
authors.affiliation: Department of Pharmacy and, Birla Institute of Technology and Science, Pilani, Rajasthan, India.
authors.forename: Mahesh
authors.initials: M
authors.lastname: Radhakrishnan
mesh_terms: D000339:Affect; D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D003863:Depression / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism* / Q000523:psychology; D048909:Diabetes Complications / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism* / Q000523:psychology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D009473:Neuronal Plasticity; D011788:Quality of Life; D012307:Risk Factors; D059326:Serotonergic Neurons / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D012701:Serotonin / Q000378:metabolism*
chemical_list: D000928:Antidepressive Agents; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D012701:Serotonin
keywords: Depression; diabetes; glucocorticoids; glycogen synthase; insulin receptors; serotonin
references.citation: Neuroscience. 2013 Jun 3;239:196-213
references.pmid: 22967840
references.citation: Brain Res. 1998 Jul 27;800(1):125-35
references.pmid: 9685609
references.citation: Br J Pharmacol. 1998 Jan;123(1):45-50
references.pmid: 9484853
references.citation: J Neurosci. 2000 Apr 15;20(8):2896-903
references.pmid: 10751442
references.citation: Neuropsychopharmacology. 2008 Jan;33(1):73-83
references.pmid: 17882234
references.citation: Front Mol Neurosci. 2010 Feb 09;3:1
references.pmid: 20162032
references.citation: Neuropsychopharmacology. 2005 Jul;30(7):1223-37
references.pmid: 15827567
references.citation: Learn Mem. 2005 Nov-Dec;12(6):646-55
references.pmid: 16287721
references.citation: Br J Pharmacol. 2010 May;160(1):1-19
references.pmid: 20331603
references.citation: Stroke. 2008 May;39(5):1600-3
references.pmid: 18369167
references.citation: Arch Gen Psychiatry. 2000 Oct;57(10):925-35
references.pmid: 11015810
references.citation: Behav Brain Res. 2011 Sep 12;222(1):230-5
references.pmid: 21458499
references.citation: Curr Drug Saf. 2009 Jan;4(1):22-9
references.pmid: 19149522
references.citation: Nutr Neurosci. 2005 Feb;8(1):57-62
references.pmid: 15909768
references.citation: Int J Clin Pract. 2007 Dec;61(12):2030-40
references.pmid: 17944926
references.citation: Behav Brain Res. 2011 Oct 31;224(2):336-43
references.pmid: 21704657
references.citation: J Clin Psychiatry. 1994 Apr;55 Suppl:18-28
references.pmid: 8077164
references.citation: Biol Psychiatry. 2009 Aug 1;66(3):259-66
references.pmid: 19368900
references.citation: Neuropsychopharmacology. 2004 Mar;29(3):461-9
references.pmid: 14628002
references.citation: Curr Drug Targets. 2006 Nov;7(11):1421-34
references.pmid: 17100582
references.citation: Prog Neurobiol. 2001 Nov;65(4):391-426
references.pmid: 11527574
references.citation: Trends Endocrinol Metab. 2011 Sep;22(9):382-7
references.pmid: 21602053
references.citation: Diabetologia. 2000 Apr;43(4):500-6
references.pmid: 10819245
references.citation: Rev Invest Clin. 1999 Sep-Oct;51(5):293-302
references.pmid: 10614139
references.citation: J Clin Psychiatry. 2000;61 Suppl 6:4-6
references.pmid: 10775017
references.citation: Diabetes Care. 2004 May;27(5):1066-70
references.pmid: 15111522
references.citation: Psychoneuroendocrinology. 2013 Sep;38(9):1607-17
references.pmid: 23465556
references.citation: Diabetes Res Clin Pract. 2010 Mar;87(3):302-12
references.pmid: 20181405
references.citation: Am J Psychiatry. 2006 Sep;163(9):1588-93
references.pmid: 16946185
references.citation: Lancet. 1966 Feb 19;1(7434):407-9
references.pmid: 4159787
references.citation: Diabetes Care. 2001 Jun;24(6):1069-78
references.pmid: 11375373
references.citation: Neurochem Res. 2008 Mar;33(3):394-400
references.pmid: 17712629
references.citation: J Clin Endocrinol Metab. 2007 Jul;92(7):2439-45
references.pmid: 17426095
references.citation: Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11056-61
references.pmid: 11005876
references.citation: World Psychiatry. 2010 Oct;9(3):155-61
references.pmid: 20975857
references.citation: J Neurosci. 2012 Mar 28;32(13):4400-16
references.pmid: 22457490
references.citation: Behav Neural Biol. 1994 Nov;62(3):237-43
references.pmid: 7857246
references.citation: Neuropsychopharmacology. 2000 Feb;22(2):108-24
references.pmid: 10649824
references.citation: Trends Neurosci. 2000 Nov;23(11):542-9
references.pmid: 11074263
references.citation: Eur J Neurosci. 2006 Mar;23(6):1539-46
references.pmid: 16553617
references.citation: J Clin Psychiatry. 2006 Dec;67(12):1974-82
references.pmid: 17194277
references.citation: Diabetes Care. 2004 Sep;27(9):2154-60
references.pmid: 15333477
references.citation: Psychosomatics. 2011 Jan-Feb;52(1):1-18
references.pmid: 21300190
references.citation: Nature. 1995 Dec 21-28;378(6559):785-9
references.pmid: 8524413
references.citation: Can J Diet Pract Res. 2006 Winter;67(4):206-8
references.pmid: 17150144
references.citation: J Neurosci. 2007 Jun 27;27(26):6956-64
references.pmid: 17596444
references.citation: J Psychiatry Neurosci. 1993 Nov;18(5):214-25
references.pmid: 7905288
references.citation: Obes Res. 2002 Oct;10(10):1049-56
references.pmid: 12376586
references.citation: Neuropsychopharmacology. 2004 Aug;29(8):1426-31
references.pmid: 15039769
references.citation: Biochem J. 2001 Oct 1;359(Pt 1):1-16
references.pmid: 11563964
references.citation: J Neurosci. 2002 Aug 15;22(16):6846-55
references.pmid: 12177182
references.citation: Neurosci Res. 2005 Apr;51(4):371-81
references.pmid: 15740800
references.citation: Diabetes. 2000 Jul;49(7):1219-23
references.pmid: 10909981
references.citation: Expert Rev Neurother. 2013 Jan;13(1):5-7
references.pmid: 23253384
references.citation: Diabetologia. 2007 Feb;50(2):431-8
references.pmid: 17151862
references.citation: Psychosom Med. 1997 May-Jun;59(3):241-50
references.pmid: 9178335
references.citation: Life Sci. 1997;60(16):1393-7
references.pmid: 9096260
references.citation: J Neuroendocrinol. 1996 Jun;8(6):433-8
references.pmid: 8809673
references.citation: Diabetes Care. 2005 Oct;28(10):2378-83
references.pmid: 16186266
references.citation: J Psychiatry Neurosci. 2004 Jul;29(4):252-65
references.pmid: 15309042
references.citation: Ophthalmic Epidemiol. 2012 Aug;19(4):196-203
references.pmid: 22775274
references.citation: Psychosom Med. 1992 Sep-Oct;54(5):602-11
references.pmid: 1438662
references.citation: Neuroscience. 1999;89(4):999-1002
references.pmid: 10362289
references.citation: Psychiatry Res. 2012 Dec 30;200(2-3):343-8
references.pmid: 22921508
references.citation: Neuroscientist. 2008 Aug;14(4):326-38
references.pmid: 18612087
references.citation: J Anim Sci. 1994 Jul;72(7):1891-8
references.pmid: 7928769
references.citation: J Biol Chem. 2013 Feb 22;288(8):5682-93
references.pmid: 23275337